ABSTRACT
Background Atrial fibrillation (AF) screening was incorporated into an abdominal aortic aneurysm screening (AAA) programme for New Zealand (NZ) Māori.
Methods AF screening was performed as an adjunct to AAA screening of Māori men aged 60-74 and women aged 65-74 registered with primary health care practices in Auckland, NZ. Pre-existing AF was determined through coded diagnoses or medications in the participant’s primary care record. Subsequent audit of the record assessed accuracy of pre-screening coding, medication use and clinical follow-up.
Results Among 1955 people screened, the prevalence of AF was 144 (7.4%), of which 46 (2.4% of the cohort) were patients without AF coded in the medical record. More than half of these were revealed to be known AF but that was not coded. Thus, the true prevalence of newly detected AF was 1.1% (n=21). An additional 48 (2.5%) of the cohort had been coded as AF but were not in AF at the time of screening. Among the 19 at-risk screen-detected people with AF, 10 started appropriate anticoagulation within 6 months. Of the 9 who did not commence anticoagulation, five had a subsequent adverse clinical outcome in the follow-up period, including one with ischaemic stroke; two had contraindications to anticoagulants. Among those with previously diagnosed AF, the proportion receiving anticoagulation rose from 57% pre-screening to 83% at 6 months post-screening (p<0.0001); among new AF the proportion rose from 0% to 53% (p<0.01).
Conclusions There is a high prevalence of AF in NZ Māori. AF screening is a feasible low-cost adjunct to AAA screening with potential to detect previously undiagnosed AF and reduce ethnic inequities in stroke. It may also prompt better coding and management of previously diagnosed AF. However, effective fail-safe measures are needed to ensure that high-risk newly diagnosed AF is managed according to best practice guidelines.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This was operational research not suitable for registration as a clinical trial.
Funding Statement
Funding for the screening programme was provided by Auckland and Waitemata District Health Boards. KP was supported by a Heart Foundation of New Zealand Hynds Senior Fellowship at the time of this study
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the project was obtained from the Northern B Health and Disability Ethics Committee on 12/3/2015 (ref 15/NTB/AM03) which was extended in 2017 to include Auckland district participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data is available on request to the corresponding author
